GLP1R and cardiovascular disorder: Among initiators of GLP1 receptor agonists versus SGLT2 inhibitors, the direction of effect modification by age in two prior studies [16, 25] was conflicting, and the direction of effect modification by cardiovascular disease and sex in our study disputes prior evidence [16, 25].